UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 2, 2025
Commission File No. 001-12575
UTAH MEDICAL PRODUCTS, INC. | ||||
(Exact name of registrant as specified in its charter) | ||||
|
|
|
|
|
UTAH |
|
|
| 87-0342734 |
(State or other jurisdiction of |
|
|
| (IRS Employer |
incorporation or organization) |
|
|
| Identification No.) |
|
|
|
|
|
7043 South 300 West | ||||
Midvale, Utah 84047 | ||||
(Address of principal executive offices) | ||||
|
|
| ||
Registrant’s telephone number: |
| (801) 566-1200 | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter). | |
| Emerging growth company ☐ |
| |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ] | |
ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
On May 2, 2025 at the Company’s annual meeting of stockholders, stockholders approved, did not approve or indicated their preference on the following matters submitted to them for consideration:
Elected Carrie Leigh as a director of the Company:
For 665,574Withheld1,762,500Broker Non-Votes 732,568
Ratified the selection of Haynie & Co. as the Company’s independent public accounting firm for the year ended December 31, 2025:
For 3,148,121Against10,548Abstentions 1,973
Approved, on an advisory basis, the compensation paid to UTMD’s named executive officers, including the Compensation Discussion and Analysis, compensation tables and narrative discussion:
For 2,383,762Against 39,327Abstentions 4,985 Broker Non-Votes 732,568
Per Company policy, Ms. Leigh tendered her resignation, which was conditioned upon acceptance by the Board of Directors. The Board of Directors voted to not accept her resignation. Per Utah law, Ms. Leigh was elected to serve a three-year term and until her successor is elected and qualified.
The Company will continue to include annual advisory stockholder votes on executive compensation in its proxy materials. Annual advisory stockholder votes will be held until at least the next required advisory vote on frequency of stockholder votes on the compensation of executives.
SIGNATURES
Pursuant to the requirements of the Securities Exchanges Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
UTAH MEDICAL PRODUCTS, INC.
REGISTRANT
Date: 5/02/2025 By: /s/ Kevin L. Cornwell
Kevin L. Cornwell
Chairman & CEO